Literature DB >> 22266155

Implementing a standardized pharmacist assessment and evaluating the role of a pharmacist in a multidisciplinary supportive oncology clinic.

Robert Mancini1.   

Abstract

Supportive care, or palliative care, in oncology patients has been a shifting paradigm in the last few years. Patients with advanced cancer experience significant symptom burden and psychosocial distress from the onset of their diagnosis and throughout treatment. The focus on cancer treatment often defers the integration of palliative care to a more "reactive" vs "proactive" approach, which can hinder symptom management. Many cancer centers are integrating palliative care programs in their practice; however, the scope of services and degree of intervention varies widely, especially with regard to the pharmacist's role. The purpose of this article is to describe the operational aspects of a multidisciplinary supportive oncology clinic at St. Luke's Mountain States Tumor Institute (MSTI). The MSTI supportive oncology clinic is a half-day clinic where complex patients are seen by a multidisciplinary team led by a nurse practitioner. The team also includes a nurse, a pharmacist, a dietitian, and a social worker. The pharmacist is responsible for medication reconciliation, which includes assessment for drug interactions, adverse effects, duplications in therapy, lack of efficacy, and untreated conditions. Within the first year of the supportive oncology clinic's operation, we saw a total of 75 patients. Use of a standardized pharmacy assessment helped to elucidate and address medication issues such as duplicate therapies (46.7% of patients), drug interactions (44%), side effects (74.7%), lack of efficacy (94.7%), and untreated conditions (73.3%). Pharmacists are uniquely trained in medication therapy management, and a thorough medication therapy review has been shown to assist other disciplines in their own assessments.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22266155     DOI: 10.1016/j.suponc.2011.09.005

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  7 in total

Review 1.  The need for community pharmacists in oncology outpatient care: a systematic review.

Authors:  Johannes Thoma; Romána Zelkó; Balázs Hankó
Journal:  Int J Clin Pharm       Date:  2016-04-07

2.  Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience.

Authors:  Carmen Lopez-Martin; Margarita Garrido Siles; Julia Alcaide-Garcia; Vicente Faus Felipe
Journal:  Int J Clin Pharm       Date:  2014-10-19

3.  Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.

Authors:  Fiorenzo Santoleri; Paola Sorice; Ruggero Lasala; Rosa Carmela Rizzo; Alberto Costantini
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Exploring the Expanded Role of Pharmacists in Advance Care Planning.

Authors:  Joseph D Ma; Alexandra Dullea; Chelsea Hagmann; Sarah Friedman; Michelle Russell; Arlene Cramer; Melanie Benn; Eric J Roeland
Journal:  JCO Oncol Pract       Date:  2021-01-08

5.  The oncology pharmacist as part of the palliative treatment team.

Authors:  Mirjam Crul; Piter Oosterhof
Journal:  Int J Pharm Pract       Date:  2019-10-01

Review 6.  Managing Polypharmacy in Older Adults with Cancer Across Different Healthcare Settings.

Authors:  Andrew Whitman; Paige Erdeljac; Caroline Jones; Nicole Pillarella; Ginah Nightingale
Journal:  Drug Healthc Patient Saf       Date:  2021-04-29

7.  Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists.

Authors:  Lonneke Timmers; Christel C L M Boons; Mathieu Verbrugghe; Bart J F van den Bemt; Ann Van Hecke; Jacqueline G Hugtenburg
Journal:  BMC Cancer       Date:  2017-02-10       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.